ReviewThe Journal of experimental medicine2023
Targeting type 2 immunity and the future of food allergy treatment.
Review in The Journal of experimental medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Climate Change and Food Allergy: Adaptations and Risks at the Intersection of Environment and Health.Comprehensive reviews in food science and food safety · 2026Review
- Pathogenic type-2 immunity beyond allergy: the role of Th2 cell heterogeneity in helminth infections.Infection and immunity · 2026Review
- Mixed Signals: T Cells as Architects of IgE Immunity.Immunological reviews · 2026Review
- DOCK8 and STAT3 cooperate to restrain IgE-inducing T follicular helper cells.The Journal of experimental medicine · 2026Article
- Allergenicity assessment of novel foods - lessons from immune endotyping of food-allergic patients.Frontiers in immunology · 2026Review
- Dendritic Cells: at the Crossroads between Oral Tolerance and Food Allergy.Current allergy and asthma reports · 2025Review
- A Multicenter Study of Factors Related to Early Implant Failures-Part 2: Patient Factors.Clinical implant dentistry and related research · 2025Article
- Advances in Food Allergy Immunotherapy: Current Strategies and Role of Antibodies Isotypes.Cells · 2025Review
- Immune tolerance to foreign antigens in the intestine: mechanisms mediated by CD4＋ T cells.BMB reports · 2025Review
- The Etiology of IgE-Mediated Food Allergy: Potential Therapeutics and Challenges.International journal of molecular sciences · 2025Review
- Secretor and non-secretor human milk oligosaccharides differentially modulate immune response in the presence of cow's milk allergen β-lactoglobulin in anFrontiers in immunology · 2025Article
- Association of cytotoxic effector memory CD8Allergy · 2025Article
- Role of human antigen-specific T cells in tolerance and IgE-mediated allergic reactions to food.Frontiers in immunology · 2025Review
- IgE versus IgG and IgA: Differential roles of allergen-specific antibodies in sensitization, tolerization, and treatment of allergies.Immunological reviews · 2024Review
- Structural characterization and mast cell stabilizing activity of Red-edge tea polysaccharide.Food chemistry: X · 2024Article
- Maintenance of caecal homeostasis by diverse adaptive immune cells in the rhesus macaque.Clinical & translational immunology · 2024Article
- The B Cell Response and Formation of Allergenic and Anti-Allergenic Antibodies in Food Allergy.Biology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
IgE-mediated food allergy affects 6-8% of the population in the United States. Type 2 immune responses are central to the pathogenesis of food allergy, but type 2 CD4+ T cell responses have been found to be heterogeneous in food allergy suggesting a division of labor between Tfh13 and peTH2 cells in promotion of IgE class switching, modulation of intestinal barrier function, and regulation of mast cell expansion. Oral immunotherapy for the treatment of food allergy incompletely targets subsets of type 2 immunity in a transient manner, but new therapeutics targeting different levels of type 2 immunity are in current or planned trials for food allergy. These new treatments and the basis for their use are the focus of this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.